- Home
- REKR vs ACRS Comparison
REKR vs ACRS Comparison
Compare REKR & ACRS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- REKR
- ACRS
- Stock Information
- Founded
- REKR 2017
- ACRS 2012
- Country
- REKR United States
- ACRS United States
- Employees
- REKR N/A
- ACRS N/A
- Industry
- REKR Telecommunications Equipment
- ACRS Biotechnology: Pharmaceutical Preparations
- Sector
- REKR Telecommunications
- ACRS Health Care
- Exchange
- REKR Nasdaq
- ACRS Nasdaq
- Market Cap
- REKR 115.1M
- ACRS 127.6M
- IPO Year
- REKR N/A
- ACRS 2015
- Fundamental
- Price
- REKR $0.99
- ACRS $1.29
- Analyst Decision
- REKR
- ACRS Strong Buy
- Analyst Count
- REKR 0
- ACRS 7
- Target Price
- REKR N/A
- ACRS $11.67
- AVG Volume (30 Days)
- REKR 3.0M
- ACRS 832.4K
- Earning Date
- REKR 05-14-2025
- ACRS 05-08-2025
- Dividend Yield
- REKR N/A
- ACRS N/A
- EPS Growth
- REKR N/A
- ACRS N/A
- EPS
- REKR N/A
- ACRS N/A
- Revenue
- REKR $46,028,000.00
- ACRS $17,777,000.00
- Revenue This Year
- REKR $14.53
- ACRS N/A
- Revenue Next Year
- REKR $17.91
- ACRS $425.96
- P/E Ratio
- REKR N/A
- ACRS N/A
- Revenue Growth
- REKR 31.76
- ACRS N/A
- 52 Week Low
- REKR $0.62
- ACRS $0.95
- 52 Week High
- REKR $2.67
- ACRS $5.17
- Technical
- Relative Strength Index (RSI)
- REKR 55.80
- ACRS 51.46
- Support Level
- REKR $0.86
- ACRS $1.20
- Resistance Level
- REKR $1.05
- ACRS $1.46
- Average True Range (ATR)
- REKR 0.07
- ACRS 0.11
- MACD
- REKR 0.02
- ACRS 0.03
- Stochastic Oscillator
- REKR 79.17
- ACRS 69.62
About REKR Rekor Systems Inc.
Rekor Systems Inc is a United States-based company. The company is engaged in providing real-time roadway intelligence through AI-driven decisions. The firm uses artificial intelligence to analyze video streams and transform them into AI-driven decisions. The company's technology and machine learning models power all solutions, including Rekor Command for transportation management, Rekor Discover for urban mobility, and Rekor Scout for public safety, and commercial use. Its geographical segments are the United States and Others, of which the majority of its revenue comes from the United States.
About ACRS Aclaris Therapeutics Inc.
Aclaris Therapeutics Inc is a clinical-stage biopharmaceutical company that operates in the United States. It focuses on developing novel drug candidates for immuno-inflammatory diseases. The company operates in two reportable segments: therapeutics and contract research. The therapeutics segment is focused on identifying and developing inventive therapies to address unmet needs for immuno-inflammatory diseases, and the contract research segment is engaged in providing laboratory services. A majority of the company's revenue is derived from the therapeutics segment. The various drug candidates in its product pipeline are Zunsemetinib, which is an Oral MK2 Inhibitor; ATI-2138, an ITJ Inhibitor; Bosakitug, ATI-052, and Lepzacitinib.